This company listing is no longer active
Calliditas Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Calliditas Therapeutics has a total shareholder equity of SEK106.8M and total debt of SEK982.5M, which brings its debt-to-equity ratio to 920%. Its total assets and total liabilities are SEK1.7B and SEK1.6B respectively.
Anahtar bilgiler
920.0%
Borç/özkaynak oranı
SEK 982.49m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | SEK 797.28m |
| Eşitlik | SEK 106.79m |
| Toplam yükümlülükler | SEK 1.64b |
| Toplam varlıklar | SEK 1.75b |
Son finansal sağlık güncellemeleri
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: CALT's short term assets (SEK1.2B) exceed its short term liabilities (SEK429.8M).
Uzun Vadeli Yükümlülükler: CALT's short term assets (SEK1.2B) do not cover its long term liabilities (SEK1.2B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: CALT's net debt to equity ratio (173.4%) is considered high.
Borcun Azaltılması: CALT's debt to equity ratio has increased from 0% to 920% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: CALT has sufficient cash runway for more than 3 years based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if CALT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.